Quick Answer
Organon & Co. reported Cash And Cash Equivalents At Carrying Value of $574.00 million for the year ending 2025.
- Organon & Co. showed a decrease of -15.0% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Organon & Co.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $141.00 million | Q2 2021: $900.00 million | Q2 2021: $730.00 million | Q3 2021: $1.01 billion | Q1 2022: $694.00 million | Q2 2022: $545.00 million | Q3 2022: $499.00 million | Q1 2023: $459.00 million | Q2 2023: $326.00 million | Q3 2023: $414.00 million | Q1 2024: $575.00 million | Q2 2024: $704.00 million | Q3 2024: $763.00 million | Q1 2025: $547.00 million | Q2 2025: $599.00 million | Q3 2025: $672.00 million.
- Over the full 6 years of available data (2020 to 2025), Organon & Co.'s Cash And Cash Equivalents At Carrying Value has grown by 4,683.3%.
- Historical annual values: Fiscal year 2025: $574.00 million | Fiscal year 2024: $675.00 million | Fiscal year 2023: $693.00 million | Fiscal year 2022: $706.00 million | Fiscal year 2021: $737.00 million | Fiscal year 2020: $12.00 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: